Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate.
Share this article
Earnings
Score 85
Bullish
Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate
Mar 24, 2026 11:27 UTC
JNJ, XLV, AMGN
Short term
Related Articles
Score 65
Bullish
Resilience of Travel Boosted Hilton Worldwide Holdings (HLT) in Q4
Mar 24, 13:40
Score 65
Bullish
Cardinal Health (CAH) Surged Following Improved Specialty Mix in Pharma
Mar 24, 13:37
Score 45
Bullish
Brown Advisory Mid-Cap Growth Strategy Bets on Medline (MDLN) in IPO
Mar 24, 13:34
Score 45
Everpure (PSTG) was Volatile Despite Strong Results
Mar 24, 13:27
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.